Zafrens, a San Diego, CA-based biotech drug discovery company, added imec.xpand to its Series A syndicate, bringing the total capital raised to USD 31m.
imec.xpand was joined by existing investors Prime Movers Lab, Kofa Healthcare, and Global Brain in this financing.
Led by Swamy Vijayan, CEO, Zafrens provides a platform that allows scientists to create and test hundreds of thousands of potential medicines in a single experiment.
The company has already demonstrated the value of its platform through collaborations with several pharmaceutical companies, focusing on multiple classes of drugs.
The new funding will enable Zafrens to expand its capacity and engage in additional partnerships with pharmaceutical companies worldwide.
FinSMEs
04/02/2025